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Abstract: The emergence of multidrug-resistant bacteria constitutes a great challenge for modern
medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and
implementation of bacteriophage therapy by Western medicine might be one solution to the problem
of increasing antibiotic failure. In some Eastern European countries phage therapy is used for
treating infectious diseases. However, while the European Medicines Agency (EMA) advised that the
development of bacteriophage-based therapies should be expedited due to its significant potential,
EMA emphasized that phages cannot be recommended for approval before efficacy and safety
have been proven by appropriately designed preclinical and clinical trials. More evidence-based
data is required, particularly in the areas of pharmacokinetics, repeat applications, immunological
reactions to the application of phages as well as the interactions and effects on bacterial biofilms and
organ-specific environments. In this brief review we summarize advantages and disadvantages of
phage therapy and discuss challenges to the establishment of phage therapy as approved treatment
for multidrug-resistant bacteria.
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1. Introduction
Antimicrobial drug resistance (AMR) is a growing challenge worldwide. The emergence of new
resistance mechanisms and their broad distribution through vertical and horizontal gene transfer is
alarming. Consequently, multidrug-resistant (MDR) bacteria are spreading globally [1]. Due to the
lack of a global tracking system, the full impact of infections with MDR bacteria is still unknown.
A recent study estimated that approximately 33,000 people died in 2015 in the European Union as
consequence of an infection with a resistant pathogen [2]. In the U.S. about 23,000 people die each
year due to infections with resistant bacteria and far more people are infected [3]. Besides the medical
aspect the socio-economic burden for health care systems is enormous [3]. Previously, the focus
was mainly on gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or
vancomycin-resistant enterococci (VRE) but in recent years gram-negative bacteria resistant against
3 or 4 classes of antimicrobial drugs or even pan-resistant bacteria are rapidly gaining importance.
In this respect, particularly noteworthy are Pseudomonas aeruginosa and Acinetobacter baumannii [4].
Many advanced therapies for cancer or autoimmune diseases, as well as transplantations are no
longer effective when patients suffer from untreatable nosocomial infections [5]. Even commensal and
opportunistic bacteria could then become problematic and jeopardize medical progress [6]. Moreover,
novel antibiotics are rare as the pharmaceutical industry has minimized research and development
programs in infectious diseases for different reasons [7]. Meanwhile, as AMR poses a major public
health concern, this issue has been discussed at the highest political levels (from the United Nations
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and the WHO to local authorities). The “Leaders´ Declaration G7 Summit, 7–8 June 2015” (held in
Elmau, Germany) stated: “We will foster the prudent use of antibiotics and will engage in stimulating
basic research, research on epidemiology, infection prevention and control, and the development of
new antibiotics, alternative therapies, vaccines and rapid point-of-care diagnostics” [8].
Already 100 years ago, a decade before the discovery of penicillin, bacteriophages (phages) were
considered for clinical use [9]. However, driven by the easy use and broader antibacterial spectrum
of antibiotics, phage therapy was seldom used during the last few decades, especially in Western
Countries [10]. Only in some countries of the former Soviet Union, such as Georgia and Russia but also
in Poland, have physicians continued to use phages and generated valuable practical experience [11].
The recent rediscovery and reintroduction of bacteriophage therapy in the Western World may possibly
provide an attractive solution to the increasing failure of antibiotics. Since then, phages have been
shown to be effective in treating bacterial infections in several experimental animal studies, as well
as in case reports and clinical trials in humans [12]. In Staphylococcus aureus induced sepsis in mice
for example, intraperitoneal (i.p.) application of phages 6 h after infection resulted in survival rates
of 67%, whereas only 10% of control mice survived [13]. Systemic phage lysin application increased
survival of mice with severe pneumonia due to S. pneumoniae from 0 to 100% [14]. Furthermore, it
was also shown that inhaled application of the bacteriophage endolysin Cpl-1 is a safe and efficient
therapy in severe pneumococcal pneumonia in mice [15]. So far, lysins seem to be more effective for
treating gram-positive bacteria and are currently being tested in clinical trials [16]. Improvement of
the enzymes’ penetrative abilities through the outer membranes is necessary for their efficient use in
gram-negative bacteria [6,17].
In P. aeruginosa lung infection, intranasal application of phages, given 24 h prior or 2 h after
infection, protected all mice from lethal infection [18]. In diabetic and nondiabetic mice with severe
bacteraemia due to i.p. injection of MDR P. aeruginosa, a single i.p. injection of phages 20 min after
bacterial injection increased survival [19]. The authors reported a survival rate of 90% in diabetic and
100% in nondiabetic mice even when treatment started 4 h after bacterial challenge. Treatment started 6
h after infection resulted in lower survival rates among diabetic mice. Further delay of treatment (12 h)
also reduced the effectiveness of phage therapy in nondiabetic mice [19]. This suggests, phage therapy
is effective in both immunocompetent and -incompetent mice. In the UK a clinical trial (double-blind
placebo-controlled, randomized phase I/II) for treatment of chronic otitis media investigated the
effect of a phage-cocktail of 6 phages against MDR P. aeruginosa. The study demonstrated physical
improvement of the patients and distinctly lower P. aeruginosa counts compared to the placebo treated
group after a single aural application. Notably, no side effects were reported [20]. These studies
along with others indicate phage therapy could be a promising prospect for the treatment of MDR
infectious diseases [21]. In laboratory animals, phages can generally be administered via different
routes for example, i.p., subcutaneous (s.c.), intramuscular (i.m.), intravenous (i.v.), oral, inhaled or
topical [22,23], with the success of phage therapy depending on both the application route and the target
organ. After parenteral application, phages are quickly distributed in the systemic circulation [23,24].
McVay et al. [24] investigated different application routes for phage therapy in mice subjected to
burn injury and subsequently infected with P. aeruginosa. Mice were treated i.m., s.c., i.p. or left
untreated. In the untreated group only 6% of mice survived, whereas 28% and 22% of animals
survived after i.m. or s.c. phage treatment, respectively. Intraperitoneal application yielded the highest
effectiveness, resulting in 88% survival [24]. Oral application was shown to be effective in treating
gastrointestinal infections [25,26], whereas topical application was successfully used to treat wound
infections [27]. Nebulization of phages for inhaled application to treat lung infections has also been
studied [28,29]. Huff et al. [30] reported that chickens, infected with E. coli into the thoracic air sac
after pre-treatment with aerosolized phages showed significantly reduced mortality compared to
untreated birds. However, Carmody et al. [31] demonstrated that intranasal inhalation of phages
was less effective when compared to systemic application in a mouse model of lung infection caused
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by Burkholderia cenocepacia. Conversely, Semler et al. [32] observed that inhaled phage therapy was
superior to i.p. injection in eliminating Burkholderia cenocepacia in murine lung infection.
Phages used for any medical application must be carefully selected and fully characterized [6].
Phages showing poor adsorption, replication and distribution should be excluded and exclusively
obligate lytic phages should be applied [33]. Temperate phages may lead to the transfer of genes
to the bacterial host, increasing its virulence by lysogenic conversion or transduction mechanisms
or transferring virulence factors or antibiotic resistance genes from prophage genomes to the host
bacteria [34,35]. The causative bacterial pathogen must be identified prior to phage selection, requiring
fast and reliable pathogen detection and susceptibility screening [35]. Alternatively, bacteriophage
cocktails including phages against the most common and typical pathogens in specific organs (e.g.,
“respiratory bacteria”) could be employed [6]. In any case, phage therapy specific infrastructure, such
as local, rapidly accessible phage libraries need to be established [6,36].
Whereas studies on effective phage therapy have been reported and extensively reviewed, there
are hardly any reports on phage therapy failures in recent years. Reports of failures mainly date back
to the early use of phage therapy [37]. In 2001, Sulakvelidze et al. [38] published a detailed overview
of phage therapy in Eastern European countries starting in the 1920s. The authors stated that failures
occur mostly due to poor phage preparations, limited knowledge regarding phage mode of action
and inconsistencies between phages and host strains. Additionally, most studies were lacking placebo
controls leading to controversial results [38]. Miedzybrodzki et al. [39] published a summary of 153
patients treated with phage therapy to different infections between 2008 and 2010 at the Hirszfeld
Institute of Immunology and Experimental Therapy in Wrocław. 39.9% of all patients showed a good
response to phage therapy and in 18.3% pathogen eradication and/or recovery was reported [39].
Moreover, there is one clinical trial from Bangladesh using phage cocktails targeting Escherichia coli
(E. coli) in children with bacterial diarrhoea reporting no advantage of phage therapy [40]. Two different
phage cocktails were tested and orally applied [40]. Phage therapy did not cause any side effects
but also did not improve the clinical outcome compared to the control group receiving standard oral
rehydration. The authors reported several limitations of the trial, including probable insensitivity of
pathogenic E. coli strains to the applied phages and the possibility of low stomach pH affecting phage
transport, as no antacid was given to the patients [40].
In this review we summarize the advantages and disadvantages of phage usage in terms of
medical application and discuss challenges to the establishment of phage therapy as an approved
treatment for MDR bacteria.
2. Advantages and Disadvantages of Phage Therapy
2.1. Phage Therapy Provides Several Advantages Over Conventional Antimicrobial Drugs Regarding Medical
Application, Some of Which Are Addressed in the Following
2.1.1. Host Specificity and Potential to Spare Microbial Flora
Lytic bacteriophages are viruses that target and infect their specific host bacteria, replicate inside
and destroy them [9]. Therefore, unlike indiscriminate antibiotics, bacteriophages are expected to spare
the physiologically resident flora, thus avoiding the development of bacterial niches that typically
result from antibiotic therapy and enable the settlement of antibiotic-resistant bacteria [41]. Moreover,
an intact microbiome contributes to innate immunity vigilance [10,42,43]. Consequently, local gut
immune response to bacterial challenge is dampened by preceding antimicrobial therapy, increasing
susceptibility to intestinal colonization and infection with pathogenic microorganisms, including
MDR bacteria [41]. Furthermore, disruption of the gut microbiome results in an impaired systemic
immune response upon bacterial stimulation and ultimately insufficient bacterial elimination [44,45].
Thus, antibiotics [44] but not phage therapy may possibly compromise immunity through microbiome
disruption, paving the way for subsequent MDR and non-MDR infections. However, this conjecture
needs to be addressed in upcoming studies. Similarly interaction of resident phages (phageome)
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with commensals as well as function and dynamics of the phageome have not yet been completely
unravelled [46].
2.1.2. Bacterial Phage Resistance
Phage infection and lysis occur independently of mechanisms used by antibiotics to kill bacteria.
Therefore, antibiotic resistance does not imply phage resistance [47]. Resistance to phages, however,
occurs naturally and to varying degrees in all bacterial cultures and communities. Different
mechanisms of resistance development have been described, including phage adsorption to bacterial
cell receptors, phage particle assembly in the bacterial cell or cell lysis processes [48,49]. Notably,
resources in the environment to isolate new phages are abundant [50]. Thus, isolation of new phages
for almost all bacterial species can be achieved quickly for example, by sampling the environment and
phage screening overnight (so called phagogram) [6] for subsequent GMP production. Consequently,
development of pan-phage resistant bacteria is very unlikely [51]. Interestingly, it has been reported
that some bacteria evolving phage resistance might over time regain sensitivity to antibiotics [52,53] or
lose their virulence [54,55].
2.1.3. Self-Replication, Self-Limitation and Anti-Biofilm Properties
Since bacteriophages can only target and infect their specific host bacteria, the lysis process is
self-limiting [47]. Phages replicate as long as their host is accessible. Consequently, to initialize or
continue the lytic cycle, phages need host bacterial cell contact, which is significantly impaired in
the case of bacteria forming biofilms, remaining intracellularly or being less abundant. Phages
encoding for depolymerases are able to degrade matrix exopolysaccharides of biofilms [56,57].
Consequently, phages and other antimicrobialsmight reach, infect and lyse bacteria inside the biofilm
more easily [56,57], which is of particular interest in case of implants (e.g., vascular or joint devices)
and airway infections [58–60]. Bedi et al. [61], showed a beneficial effect on the eradication of a
biofilm formed by Klebsiella pneumoniae when antibiotic and phage were combined. Another study
demonstrated that phage OMKO1 was able to reduce bacterial densities in a P. aeruginosa in vitro
biofilm assay [62]. Moreover, this phage alone or in combination with an antibiotic was more effective
in reducing the biofilm than antibiotics alone [62]. Nevertheless, the effectiveness depends on the
phage and the host bacteria. Darch et al. [63] examined the ability of two phages to inhibit bacterial
dissemination in a model of aggregate formation by P. aeruginosa. The two phages were able to kill
P. aeruginosa and inhibit aggregate formation when applied simultaneously with the bacteria [63].
However, when applied after aggregate formation was already established, the authors did not observe
complete elimination of aggregates, most likely due to exopolysaccharide production. Still phage
application could prevent formation of new aggregates by proliferating bacteria [63]. Full elimination
of a complex mature biofilm with one single phage seems unlikely but phage cocktails and combined
therapy with antibiotics could be a potential strategy [56,57,64].
2.2. Some of the Disadvantages of Phage Therapy Are Addressed by the Following Aspects
2.2.1. Activity against Intracellular Pathogens
Phages are unlikely to be able to actively enter eukaryotic cells. Therefore, phages are less
effective against intracellular bacteria for example, Mycobacterium tuberculosis, as well as against
intracellularly-surviving and persistent clones of extracellular bacteria, for example, A. baumannii [38].
2.2.2. Liberation of Endotoxins
Although it seems unlikely that therapy with purified phages leads to relevant toxic side effects,
major concerns encompass the potentially massive liberation of bacterial endotoxins after bacterial
lysis. Similar observations have been made with the use of certain antibiotics [65], as well as
immune reactions to bacterial components including endotoxin present in crude phage lysates [66].
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Confrontation with large amounts of bacterial endotoxins could lead to clinical deterioration of septic
patients [67,68]. However, Dufour et al [69] reported for two different E. coli phages fewer released
endotoxins in vitro compared to β-lactams, while the phage-evoked endotoxin level was comparable
to that evoked by amikacin [69].
2.2.3. Potential Risk of Anaphylaxis
Phages are members of microbial communities and are present in the environment as well as on
and in the human body [70,71]. Despite this, therapy with phages requires a higher titre compared
to their naturally occurring numbers. Moreover, the use of high phage titres in patients bears the
theoretical risk of inducing extreme immune responses like anaphylaxis [38]. Although theoretically
possible, anaphylaxis due to phage therapy has never been reported and does not seem to be a major
concern in phage therapy [11,47].
2.2.4. Immune Response to Phages
Being composed of proteins and nucleic acids, phages in general are considered as innately
non-toxic [47,72]. However, there is evidence for non-specific immunomodulatory characteristics
of phages [73], as well as activation of phagocytosis and anti-inflammatory properties [74]. Roach
et al. demonstrated that presence of neutrophils is necessary for phage therapy success against
P. aeruginosa [75]. Moreover, a recent in vivo study revealed that an increased number of phages in the
gut (applied via drinking water to mice) can aggravate colitis in a TLR9 and IFN-gamma dependent
manner and that phages inside the gut could stimulate non-specific and phage-specific immunity [76].
It is also possible that the human immune system may recognize phages as foreign antigens
and produce phage-neutralizing antibodies depending on the application route [77]. In order to
minimize the risk of side-effects due to impurities, it is necessary in at least parenteral application
routes to use highly purified phage preparations [78]. For a widespread use of human phage therapy
according to Western European medical standards, more scientific evidence is needed. In particular
further investigation is warranted in the areas of immunological reactions following single or repeated
phage application, pharmacokinetics and -dynamics and interaction with bacterial biofilms and
commensal flora.
3. Challenges in Clinical Use of Phage Therapy
3.1. Current State of Phage Therapy
Experience with human phage therapy dates back more than 100 years in Georgia, Russia and
Poland. However, Jault et al [79] stated that these countries have not developed “evidence-based
medical standards” so far and “if there are any, they are only available in Russian” [79]. Especially at
the ELIAVA Institute of Bacteriophage in Tbilisi, significant effort has been put into the characterization
and development of phage products. Phage cocktails are routinely used for treatment, including
prescribed medicine and self-medication (over the counter products) [80,81]. In Poland, phage research
is predominantly carried out at the Hirszfeld Institute of Immunology and Experimental Therapy in
Wrocław [82]. The institute focuses on preparation of specific phage lysates for individual patients
subsequent to identification of causative pathogens from patient’s samples. After Poland’s accession
to the EU, the Phage Therapy Unit, an outpatient clinic working according to EU regulations, was
established. In this unit phages are applied under terms of experimental treatment in accordance
with the Declaration of Helsinki and Polish regulations [83,84]. Despite years of practical experience,
numerous case reports [39,85–87] and data from clinical studies including investigations of immune
response [20,88–93], the lack of peer-reviewed controlled clinical trials still renders an evidence-based
evaluation of phage therapy by Western standards difficult [84]. Marketing authorization of phage
therapy in Western Europe depends on several conditions, including production of phage preparations
according to good manufacturing practice (GMP) conditions, the issue of patentability and official
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approval by European Authorities [35]. In the following section, we will discuss regulatory, production
and clinical trial challenges to the establishment of phage therapy as a regulatory approved therapy.
3.2. Regulatory Challenges
The European Medicines Agency (EMA) held a workshop in 2015 together with relevant
stakeholders including academia, industry, policy makers and patient organizations to identify
possibilities for the development of bacteriophage-based therapies against bacterial infections [94].
Approximately 60 experts discussed practical and regulatory issues related to phage licensing pathways
as opposed to conventional medicine, for example, whether or not the EU Directive 2001/83/EC
(relating to medicinal products for human use) might be applicable for phages [84,94,95]. As EMA has
not licensed any phage products so far, it is not clear which pathway to approval is most promising.
Moreover, modification or updating of existing phage cocktails with new phages, necessities with
regard to developing phage resistances or changing pathogens, are not yet covered by existing
regulations [84]. Hence, currently new time and cost intensive re-production and re-approval under
GMP conditions would be required [84]. As phage biology (and bacterial co-evolution) implies the
necessity for fast turnover of specific phages in clinical use, the process of development and approval
needs to be shortened, which could be achieved by approval of production processes rather than
specific phage products. Additionally, it must be clarified whether each phage of a cocktail or the
complete cocktail is considered a medicinal product and needs regulatory approval.
3.3. Production Challenges
For a broad medical application, phages have to be produced in large scale by pharmaceutically
licensed facilities. Consequently, there will be a commercial interest in the optimization of processes
and the reduction of costs, which is indeed not trivial as non-linear dynamics of phages and host
bacteria have to be considered [96]. In order to scale up phage manufacturing Krysiak-Baltyn et al. [96]
proposed a computational model appropriate for modelling phage production, including varying
infection parameters. This model might be suitable to cut costs or to improve productivity [96]. With
the increasing interest in phage therapy, the issue of intellectual property (IP) protection comes to the
fore [97]. To date the options for IP protection of naturally occurring phages are limited because there
are abundant resources to isolate phages from the environment [36]. Therefore, other possibilities
should be considered. For example, there are several options to implement IP protection in the
manufacturing process, for example, every new phage, new preparation (consisting of approved
single phages) or the production method, in order to increase attractiveness of the field to economic
stakeholders [39,98,99].
3.4. Clincial Trial Challenges and Ongoing Projects
Recently, results of the first European randomized, controlled phase 1/2 trial aimed at evaluating
the efficacy and tolerability of a topical applied phage cocktail (PP1131) against P. aeruginosa in burn
wounds (PhagoBurn, www.phagoburn.eu) have been published [79]. The authors reported that
patients treated with the phage cocktail showed slower decrease of bacterial burden in the burn
wounds compared to patients receiving standard therapy (1% sulfadiazine silver emulsion cream).
This finding must be interpreted with caution, as the study had several limitations: The patient cohort
was relatively small (standard therapy n = 13, PP1131 n = 12) and inhomogeneous, as patients treated
with phages were older, were burned to a lesser extent and showed higher bacterial burden at therapy
start compared to those treated with standard therapy [79]. Importantly, there have been some stability
issues of the phage cocktail used, as the authors reported a decrease in plaque forming units (pfu)
during the study, which was associated with the application of a lower than intended dose of active
phages. Future studies should address stability and shelf-life of each phage product including phage
cocktails. The relatively large cocktail of 12 phages resulted in double the expected production time
and thus reduced time to recruit patients [79]. Although the study terminated prematurely due to
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insufficient efficacy, it was the first trial using a cocktail of phages purified according to GMP standards
and approved by national health regulators [79].
The German Phage4Cure (http://phage4cure.de/) consortium aims to address the safety,
tolerability and efficacy of a purified inhaled bacteriophage cocktail against chronic airway infection
with P. aeruginosa [100]. The goal of the four project partners (Fraunhofer Institute for Toxicology and
Experimental Medicine, ITEM; the Leibniz Institute DSMZ-German Collection of Microorganisms
and Cell Cultures GmbH; Charité–Universitätsmedizin Berlin; and Charité Research Organisation
GmbH, CRO) is to pave the way for clinical applications of bacteriophages in Germany and Western
Europe by applying GMP standards in the entire production chain of the phage product and by
getting approval for phage therapy from regulatory authorities [100]. The project gained governmental
financial support (funded by the German Federal Ministry of Education and Research) and regulatory
authorities, namely BfArM (Federal Institute for Drugs and Medical Devices), are closely involved [100].
The Phage4Cure team is focusing on bacteriophages targeting P. aeruginosa, which is characterized by
high abundance, rapid growth, distinct ability to form biofilms and a highly flexible genome, aspects
that contribute its wide distribution and difficulties in combatting this bacterium [101]. P. aeruginosa
is intrinsically resistant to several classes of antibiotics and there is increasing evidence of strains
resistant to antibiotics of last resort [101]. Immunocompromised patients and patients with pre-injured
lungs, particularly those with cystic fibrosis (CF) are frequently colonized by bacteria with 80% of
CF patients older than 18 years harbouring P. aeruginosa [102]. CF is a genetic disorder caused by a
mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that affects the lungs,
as well as the pancreas, liver, kidneys and intestine [103]. Non-cystic fibrosis (non-CF) bronchiectasis
represents a chronic and heterogeneous airway disease with diverse aetiology. Like patients with
CF, non-CF bronchiectasis patients are highly susceptible to pulmonary infections. Most patients
with bronchiectasis are colonized with antibiotic resistant bacteria (e.g., Acinetobacter, Pseudomonas,
Burkholderia), with P. aeruginosa infections being associated with poor prognosis [104–108]. As patients
with bacterial colonization but not infection are clinically relatively stable, effectiveness and tolerability
of inhaled phage therapy may well be tested. Consequently, P. aeruginosa colonization in CF and non-CF
bronchiectasis patients was chosen by the consortium Phage4Cure as therapeutic target to pave the way
to a clinical trial with phages produced under GMP conditions and, ultimately, to regulatory approval.
On the basis of their expertise, each partner will work on different aspects of the project, ranging from
phage selection and characterization (DSMZ; as discussed by Korf et al. in this issue of the journal) to
drug production and stability testing (ITEM). Following phage production and thorough preclinical
evaluation (Charité and ITEM), clinical phase 1 and 2 trials are planned to be performed at Charité.
If successful, the project may lead to first-time establishment of phages as approved inhaled therapy
for CF and non-CF bronchiectasis patients in Germany and may possibly provide a GMP-compliant
phage purification platform process as a blueprint for phage therapy development with respect
to other indications [6,100]. Further projects related to the implementation of phage therapy in
Western Europe include PhagoMed and PhagoFlow. The biotech company PhagoMed Biopharma
GmbH (https://www.phagomed.com/), based in Vienna, focuses on the development of phage-based
therapies for bacterial infections [109]. Supported by grants and private investments, PhagoMed
evaluates, inter alia, the treatment of infected prostheses with phages. PhagoFlow aims at testing
a magistral prescription of phages in patients with wounds infected by MDR bacteria and is being
carried out at the military hospital Berlin, together with DSMZ and Fraunhofer ITEM [110]. Magistral
preparation in the EU is defined as “any medicinal product prepared in a pharmacy in accordance with
a medical prescription for an individual patient” (Article 3 of Directive 2001/83 and Article 6 quarter,
§ 3 of the Law of 25 March 1964) [111] and is therefore a practical way to produce treatments adjusted
to the special needs of an individual without being dependent on commercial manufacturing [111].
In Belgium, the magistral preparation is already used for phages [111] and could provide a solution
for individual patients but cannot cover the requirements of a larger patient cohort. GMP and GCP
guidelines also apply for magistral applications. To promote a European solution to conquer the
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regulatory challenges of personalized and phage based medicinal products, the idea of a “biological
master file”, a concept already existing for chemical drugs but not for biologically active substances,
was suggested by Fauconnier [112]. In summary, the main prerequisites for the establishment of
a bacteriophage-based therapy are specific regulations for phage-based pharmaceuticals, increased
clinical trial evidence and an infrastructure for efficient and rapid phage provision [6,36,113].
After decades of sleeping like Rip van Winkle, phage therapy is currently awakening in Western
Europe due to the noise made by antimicrobial resistance, causing relevant research activity in
the field. New valuable data addressing current concerns regarding clinical use of phages can be
expected. However, whether phages will be approved by regulatory authorities and get market access
is currently unpredictable.
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